109,542 Shares in Humacyte, Inc. (NASDAQ:HUMA) Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in Humacyte, Inc. (NASDAQ:HUMA - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 109,542 shares of the company's stock, valued at approximately $596,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.09% of Humacyte as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. nVerses Capital LLC bought a new position in shares of Humacyte during the second quarter valued at about $28,000. Concurrent Investment Advisors LLC purchased a new position in shares of Humacyte during the third quarter valued at about $75,000. Principal Financial Group Inc. bought a new position in Humacyte in the second quarter worth about $83,000. FORA Capital LLC bought a new stake in Humacyte during the 3rd quarter valued at approximately $96,000. Finally, Profund Advisors LLC purchased a new position in shares of Humacyte during the 2nd quarter worth approximately $97,000. 44.71% of the stock is owned by institutional investors.

Insider Transactions at Humacyte

In related news, CEO Laura E. Niklason sold 261,369 shares of Humacyte stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $4.40, for a total transaction of $1,150,023.60. Following the transaction, the chief executive officer now directly owns 1,730,884 shares in the company, valued at approximately $7,615,889.60. The trade was a 13.12 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Brady W. Dougan sold 427,459 shares of the company's stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total value of $1,855,172.06. Following the completion of the sale, the director now owns 1,992,253 shares of the company's stock, valued at approximately $8,646,378.02. The trade was a 17.67 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,500,000 shares of company stock worth $6,606,799 in the last quarter. Company insiders own 11.20% of the company's stock.

Humacyte Stock Performance

Shares of HUMA stock traded up $1.18 on Friday, reaching $4.64. The stock had a trading volume of 75,231,266 shares, compared to its average volume of 2,735,148. The stock has a market cap of $583.99 million, a P/E ratio of -3.46 and a beta of 1.38. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.10 and a current ratio of 1.10. The company has a 50 day simple moving average of $4.83 and a 200 day simple moving average of $5.85. Humacyte, Inc. has a 1 year low of $2.48 and a 1 year high of $9.97.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on HUMA shares. Piper Sandler set a $6.00 price target on Humacyte and gave the stock a "neutral" rating in a research note on Friday, October 18th. EF Hutton Acquisition Co. I raised shares of Humacyte to a "strong-buy" rating in a research report on Monday, September 9th. BTIG Research restated a "buy" rating and issued a $10.00 price objective on shares of Humacyte in a report on Friday, October 18th. D. Boral Capital reiterated a "buy" rating and set a $25.00 target price on shares of Humacyte in a report on Friday. Finally, HC Wainwright restated a "buy" rating and issued a $15.00 price target (up previously from $12.00) on shares of Humacyte in a research note on Friday. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $13.43.

Humacyte Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.